Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes] 

Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD

Articles

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer discussed the wide-spread applicability of scalp EEG and the potential for machine learning models to help predict epilepsy surgery outcomes. [WATCH TIME: 4 minutes]

Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]

Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD

Dean and chief academic officer at the University of Miami Miller School of Medicine.

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA 

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Research from IJMSC September 2024

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Introduction to CMSC Best Practices in Multiple Sclerosis Therapies Roundtable 

Best Practices in Multiple Sclerosis

Best Practices in Multiple Sclerosis: Discussion

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis

Therapeutic Selection in Relapsing Multiple Sclerosis: Key Concepts

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis: Discussion

Therapeutic Selection for Progressive Multiple Sclerosis

Considerations in Therapeutic Selection for Progressive Multiple Sclerosis

Therapeutic Selection for Progressive Multiple Sclerosis: Discussion

Patients With Features of Aggressive Multiple Sclerosis or Poor Prognosis

Safety Concerns and Discussion: Highly Active Multiple Sclerosis

Therapeutic Goals of Treating Multiple Sclerosis 

Indicators of Suboptimal Therapies 

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis

Best Practices for Treating Pediatric Patients

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis: Discussion 

Best Practices for DMTs for Pregnant Patients With Multiple Sclerosis  

Multiple Sclerosis Drugs During Pregnancy 

Relapse Therapy and Postpartum Care for Pregnant Patients With Multiple Sclerosis 

Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis 

Discussion: Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis

Issues in Therapeutic Selection for Multiple Sclerosis 

Considerations When Selecting an Optimal DMT for Multiple Sclerosis Treatment 

Best Practices in Multiple Sclerosis Therapies: Future Perspectives

Expert Insights on the Best Practices of Multiple Sclerosis: Summary

Closing Thoughts: CMSC Best Practices in Multiple Sclerosis Therapies Roundtable

An expert-led panel discuss the best practices and different treatment considerations in multiple sclerosis.

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

CMSC Best Practices in Multiple Sclerosis Therapies Roundtable